Alnylam president Barry Greene leaves after 17 years, handing position over to Yvonne Greenstreet as biotech looks toward profitability
After 17 years helping Alnylam steer control of buzzy but unproven science they promised could change medicine, president Barry Greene is leaving the RNAi biotech just as that technology is beginning to hit prime time.
Leaving to “pursue outside interests in the biopharmaceutical industry,” the longtime executive will hand over the reins on October 1 to current COO Yvonne Greenstreet. Greenstreet, a former Pfizer and GlaxoSmithKline executive, inherits the high-profile spot at a company that’s proven its tech can work in rare diseases but now faces the daunting task of turning a couple successes and a new mountain of cash into drugs that are broadly applicable and, crucially, profitable.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.